Designing medication therapy around people living with chronic pain

Chronic pain reshapes the daily rhythm of roughly one in five Australians, placing around 3.6 million adults somewhere between an occasional ache and a life governed by discomfort. Pharmacists in Parramatta, Perth and Brisbane see those people across the calendar, whether they are refilling old scripts, picking up new prescriptions, or asking about something they have not yet tried. How those conversations unfold shapes whether medication becomes a useful tool or another source of frustration.

Australia's regulatory environment for pain medicines has tightened over the past decade, and the pharmacist's brief has expanded in step. Codeine was rescheduled in February 2018, Real Time Prescription Monitoring now operates in every state and territory, and ongoing Therapeutic Goods Administration reviews continue to reshape labelling. Layered onto that, the Pharmaceutical Benefits Scheme governs what patients can realistically afford. Sitting inside those pressures, a patient-centred approach to medication therapy for chronic pain keeps clinical decisions aligned with what people actually want from their care.

Hearing the whole story before reaching for the prescription

A pharmacist reviewing a script often holds a more candid portrait of someone's pain than the prescriber who wrote it. The brief chat at the counter captures missed shifts on a construction site, the cancelled yoga class, and the broken sleep no analgesic seems to fix. Those details rarely appear in clinical notes but quietly drive adherence, mood and willingness to try non-drug strategies.

Open prompts work better than the typical adverse-effect checklist. Inviting the patient to describe a typical bad day, naming what pain has stolen, and asking what a good day might look like surfaces the biopsychosocial reality any regimen must respect. Pharmacists across regional Victoria have found that even five minutes of framing reveals over-the-counter layering, alcohol use and family stress that would otherwise stay invisible. Listening is the first clinical act, not an optional extra.

Documenting those priorities, however briefly, turns follow-up reviews into an iterative partnership. Patients who feel heard early are more likely to raise concerns about side effects promptly, more willing to discuss tapering when it is suggested, and more inclined to embrace the non-drug elements of a multimodal plan. That trust is what allows the regimen to change shape as life changes.

Reconciling every pill in the bag

Structured medication review sits at the heart of pharmacist-led chronic pain care, and several funded pathways make the work both rigorous and reimbursable. MedsCheck, Diabetes MedsCheck and Home Medicines Review let pharmacists in Adelaide, Hobart, Cairns and smaller towns sit down with patients and walk through every tablet, capsule, patch and herbal preparation they are actually taking.

Reconciliation goes well beyond listing scripts. It involves checking for duplicative opioids across prescribers, identifying benzodiazepines layered on top of gabapentinoids, and flagging combinations that raise the risk of serotonin syndrome or respiratory depression. The pharmacist also evaluates how each medicine maps to the patient's stated goals, whether that means lifting a grandchild, returning to part-time cleaning work in western Sydney, or simply sitting through a meal without pain interrupting. When a medicine no longer serves a goal, the conversation about deprescribing becomes much easier to begin.

PBS constraints, Safety Net thresholds and authority requirements shape what is feasible, particularly for pensioners who sometimes ration doses to make scripts last longer. Naming that reality openly, and exploring whether an authority script, a brand substitution, or a fully subsidised alternative might help, shows the pharmacist working alongside the patient inside the system. Those conversations are quietly some of the most therapeutic moments in community pharmacy.

Tailoring pharmacotherapy to personal goals

No two chronic pain presentations are identical, and a patient-centred regimen reflects that variability. Rather than defaulting to the WHO analgesic ladder in its original form, contemporary Australian guidance emphasises multimodal prescribing, with non-opioid options, adjuvants such as duloxetine, amitriptyline or pregabalin, and topical agents often considered before any Schedule 8 medicine is touched.

Goal-based prescribing means asking what functional milestone a patient wants to reach in the next three to six months and shaping the regimen around that answer. For a fifty-eight-year-old tradesperson in Fremantle keen to return to light duties, the priority might be daytime analgesia without sedation; for a retiree in Hobart whose pain drives social withdrawal, the priority may be relief that allows participation in a community walking group. The pharmacist's role is to explain the realistic trade-offs of each option, including expected benefit, common adverse effects, time to onset, and PBS paperwork involved.

Non-pharmacological strategies earn their place in the review as well. Heat, pacing, sleep hygiene, gentle resistance work and psychologically informed approaches such as acceptance and commitment therapy are increasingly recognised as core components of modern pain care, not optional extras. The pharmacist can reinforce those referrals, check they have actually been offered, and ensure medicines do not undermine them, for example by flagging sedating regimens that interfere with supervised exercise.

Practical levers during pain consultations

A short menu of levers pharmacists can build into routine pain conversations:

• Mapping every analgesic to a named functional goal recorded in the patient notes
• Setting review intervals tied to that goal rather than to a fixed script length
• Watching for early adverse effects such as constipation, dizziness or low mood
• Asking at every review whether the patient feels closer to or further from their stated goal

These levers keep the regimen honest. When the answer drifts away from the goal, the conversation about adjustment or taper can begin earlier and with less resistance.

Monitoring, tapering and safety nets

Once a patient-centred regimen is in place, monitoring is what keeps it safe. Real Time Prescription Monitoring, operating across every Australian state and territory, gives community pharmacists a near real-time view of recent dispense events. Used well, it prompts a quiet conversation about overlapping prescriptions or escalating doses rather than a refusal to dispense on principle.

Tapering conversations benefit from the same patient-centred framing used at the start of therapy. When functional goals have plateaued or adverse effects have accumulated, slow opioid reduction, often by roughly five to ten per cent of the daily dose every few weeks, is generally better tolerated than abrupt change. Pharmacists can prepare written tapering calendars, suggest non-opioid bridges such as paracetamol or topical NSAIDs, and arrange closer review points during the vulnerable early weeks. Family members are often quietly relieved when the conversation moves in that direction with their input.

Safety nets deserve attention regardless of dose. Take-home naloxone has been available through Australian community pharmacies since 2019, and pharmacists are well placed to offer it to anyone on regular full-agonist opioids, particularly when co-prescribed sedatives or a history of substance use disorder are present. Routine laxatives for opioid-induced constipation, periodic vitamin D review in less mobile patients and seasonal influenza vaccination all sit inside the pharmacist's preventive scope and quietly reduce harm over time.

Safety routines worth embedding in practice

• Building naloxone offers into every review of high-dose or long-term opioid therapy
• Using RTPM flags to schedule a same-week pain review rather than a refusal at the till
• Preparing written taper plans the moment an opioid dose has crept upward unintentionally
• Documenting carer involvement so family members can flag concerns without patient embarrassment

These routines turn safety conversations from reactive to preventive, and reassure patients that any taper will be planned rather than punitive.

Working alongside the wider healthcare team

Chronic pain rarely sits within a single clinician's remit, and patient-centred medication therapy depends on respectful collaboration across professions. Community pharmacists are often the ones who notice subtle changes, so contacting a general practitioner to clarify doses, request shared-care arrangements or escalate adverse effects is a daily rhythm in this area.

When a pain specialist, addiction medicine physician, physiotherapist, psychologist or exercise physiologist is involved, the pharmacist frequently becomes the most consistent point of contact, reconciling recommendations that might otherwise drift apart between visits. Allied health referral pathways, particularly through Primary Health Networks in cities like Melbourne and Brisbane, can make those handovers smoother. Pharmacists engaged with Pharmacy Health Connect and similar programs in New South Wales and Victoria are quietly shaping how allied health, primary care and tertiary pain services mesh around community-based patients.

For pharmacists looking to extend their own pain care practice, accessible resources matter beyond the PBS formulary. Stepping briefly outside the Australian context, international pain resources can offer practical starting points on multimodal care models, particularly for adjuvant and non-drug therapies that complement local prescribing.

Standing up patient-centred medication therapy for chronic pain in your own pharmacy does not require a grand redesign. Pick one conversation template to refine this month, identify the local GP who welcomes a quick phone call about pain reviews, and decide where naloxone will sit on your workflow. Australian pharmacists already have the regulatory reach, the dispensing data and the daily contact hours to make this kind of care the norm rather than the exception. For ongoing reflections on how pharmacists across the world are shaping chronic pain care, Jonathan Laird's blog is a worthwhile weekly read, and the work now is simply to practise it, one conversation at a time.